MA5-13961

antibody from Invitrogen Antibodies

Targeting: NKX2-1 BCH, NKX2A, TITF1, TTF-1, TTF1

Provider product page for MA5-13961

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [71]
Comments [0]
Validations
Immunohistochemistry [2]
Other assay [2]

Submit

Product number: MA5-13961 - Provider product page
Provider: Invitrogen Antibodies
Product name: Nkx2.1 Monoclonal Antibody (8G7G3/1)
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Description: MA5-13961 targets Thyroid Transcription Factor 1 in IF and IHC (P) applications and shows reactivity with Human, mouse, and Rat samples.
Antibody clone number: 8G7G3/1
Concentration: 0.2 mg/mL

NKX2-1 protein structure - MA5-13961 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 P4HA2-mediated collagen synthesis attenuates cancer cell differentiation Western blot analyses of expression levels of TTF-1 and Mucin 5B in H1299 control and H1299 RASSF1A cells with band intensity quantification ratio determine by ImageJ analyser. Representative images of H&E and immunohistochemical staining for lung differentiation markers TTF-1 and Mucin 5B for at least two independent regions of n = 4 H1299 control and n = 2 H1299 RASSF1A primary tumours at day 17 with quantification (right) of TTF-1 based on nuclear intensity. Scale bars: 100 mum. Statistical significance was determined by Student's t -test (two-tailed). Error bars represent the mean +- SEM Representative images of immunofluorescence staining of spheroids grown in collagen matrix (2 mg/ml) for differentiation markers TTF-1 (Green) and Mucin 5B (Red). Scale bars: 50 mum; Zoom: 10 mum. Bright-field images of H1299 control and H1299 RASSF1A spheroid differentiation on Matrigel matrix after 24 h when 3D spheroids were seeded on three-dimensional substrate. Scale bars: 200 mum. Source data are available online for this figure.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 diABZI-4 inhibits SARS-CoV-2 replication in lung epithelial cells. (A) Native immunoblot of STING dimerization from ACE-A549 cells treated with 0.1 muM of diABZI-4 for the indicated times. (B) Immunoblot analysis of p-IRF3, STING, ACE2 and beta-actin from ACE2-A549 cells treated with 0.1 muM of diABZI-4 for the indicated times. (C-D) QPCR analysis of IFNbeta (C) and TNF-alpha (D) mRNA expression in ACE2-A549 cells treated with 0.1 muM of diABZI-4 for 1.5 hours. (E) QPCR analysis of HCoV-OC43-N mRNA from ACE2-A549 cells infected with HCoV-OC43 0.1 MOI for 24 hours with or without pre-treatment of 0.1 muM diABZI-4. (F) TCID50 assay of conditioned medium from ACE2-A549 cells treated as in E for 48 hours. (G-I) QPCR analysis of SARS-CoV-2-N (G), Nsp14 (H) and ORF1 (I) mRNA from ACE2-A549 cells infected with SARS-CoV-2 0.1 MOI for 24 hours with or without pre-treatment of 0.1 muM diABZI-4. (J) Genome copy number analysis on conditioned medium from ACE2-A549 cells treated as in I. (K) TCID50 assay of conditioned medium from ACE2-A549 cells infected with SARS-CoV-2 0.1 MOI for 48 hours with or without pre-treatment of 0.1 muM diABZI-4. ( L ) Genome copy number analysis on ACE2-hESC-iAT2 cells infected with SARS-CoV-2 0.1 MOI for 72 hours with or without pre-treatment of 0.1 muM diABZI-4. (M) Immunofluorescence analysis of SARS-CoV-2 spike, Pro-SP-C and NKX2.1 in hESC-iAT2 cells infected with SARS-CoV-2 0.1 MOI for 72 hours with or without pre-treatment of 0.1 muM diABZI-4 A-B